Clinical Trials Logo

Heart Failure With Normal Ejection Fraction clinical trials

View clinical trials related to Heart Failure With Normal Ejection Fraction.

Filter by:

NCT ID: NCT03310099 Recruiting - Obesity Clinical Trials

Unsaturated Fatty Acids Enriched-diet to Improve Cardiorespiratory Fitness in Obese Patients: a Feasibility Study

Start date: October 16, 2017
Phase: N/A
Study type: Interventional

The investigators hypothesize that a dietary intervention aimed at increasing unsaturated fatty acids (UFA) consumption is feasible and has the potential to improve cardiorespiratory fitness in symptomatic obese heart failure with preserved ejection fraction (HFpEF) patients.

NCT ID: NCT03289481 Recruiting - Clinical trials for Heart Failure With Normal Ejection Fraction

Treatment of HFpEF With Nitrate Supplement

Start date: March 20, 2017
Phase: N/A
Study type: Interventional

The objective of this project is to determine if Neo40, a nitric oxide generating lozenge, when consumed twice daily by subjects with HFpEF, will increase exercise tolerance, decrease symptoms and improve quality of life for patients.

NCT ID: NCT03269630 Not yet recruiting - Healthy Clinical Trials

New Orleans Pulmonary Hypertension Biobank

NO-PH Biobank
Start date: October 2017
Phase: N/A
Study type: Observational

Pulmonary hypertension (PH) is a serious condition characterized by a mean pulmonary artery pressure >=25mmHg on right heart catheterization (RHC). Despite advances in PH care, outcomes are still sub-optimal and further research is required into the pathobiology of the disease and development of biomarkers that can guide clinical care. The investigators are establishing a biobank to collect samples (blood, urine, stool) from patients with pulmonary hypertension, patients at high risk for pulmonary hypertension, healthy controls, and patients undergoing right heart catheterization. Specimens will be stored for future investigations.

NCT ID: NCT03251183 Not yet recruiting - Clinical trials for Heart Failure With Normal Ejection Fraction

Validation of CMR Against Invasive Haemodynamics in Patients With HFpEF

Start date: September 2017
Phase: N/A
Study type: Observational

Heart failure (HF) currently affects app. 2% of the western population and app. 10% of people >75 years. In about 50% of patients with symptomatic HF ejection fraction (EF) is preserved (HF-PEF). Once patients develop symptoms, the prognosis is poor with 25% mortality at 1 year and 50% mortality at 5 years. HFpEF is one of the major unresolved areas in clinical cardiology. The diagnosis of HFpEF remains a diagnosis of exclusion and currently no non-invasive measure provides a clear diagnosis. Cardiovascular magnetic resonance (CMR) provides non invasive and radiation free evaluation of heart structure and function. New CMR parameters offer the possibility to describe the underlying pathological and physiological changes associated with HFpEF. The investigators propose to undertake the first systematic comparison between a CMR protocol and invasive haemodynamics as the best possible gold standard, as well as define the histopathological drivers in myocardial biopsies. The investigators will also examine the relations with tissue and serological biomarkers implicated in HFpEF and the role with standard and novel parameters by echocardiography. If successful, this study will provide tools for a reliable and accurate non-invasive characterization of patients with HFpEF, supporting the diagnosis and grading the severity of disease. This study will provide a reference basis for future diagnostic algorithms in HFpEF, both, for CMR and echocardiography, but also for their relative value in comparison to blood markers or invasive testing. In addition to a new pathway to acess the effects of current and novel therapeutic interventions, the investigators see the greatest potential in identifying a disease stage where the myocardial injury may be reversible.

NCT ID: NCT03226652 Recruiting - Heart Failure Clinical Trials

Heart Function in Patients Assessed for Sleep Apnoea

Start date: July 24, 2017
Phase: N/A
Study type: Observational

This study aims to determine the prevalence and prognosis of heart failure with preserved ejection function (HFpEF) among patients being assessed for sleep disordered breathing (SDB).

NCT ID: NCT03195660 Active, not recruiting - Sleep Apnea Clinical Trials

Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study

Start date: June 26, 2017
Phase: N/A
Study type: Interventional

This study is designed to demonstrate feasibility of study conduct and that acceptable adherence to adaptive servo-ventilation (ASV) therapy can be achieved in recently hospitalized HFpEF patients with moderate to severe sleep apnea. All subjects meeting the criteria will receive ASV therapy.

NCT ID: NCT03186833 Recruiting - Clinical trials for Heart Failure With Normal Ejection Fraction

The Heart Failure With Preserved Ejection Fraction (HFpEF) Pathophysiology Study.

Start date: June 6, 2017
Phase: N/A
Study type: Observational

The study addresses the hypothesis that a gradual build-up in arterial resistance and microvascular endothelial dysfunction due to common comorbidities such as hypertension and diabetes mellitus, on top of age related vascular and cardiac changes (mainly fibrosis and hypertrophy), is responsible for HFpEF. The HFpEF syndrome is commonly seen in elderly subjects (often females) with hypertension and diabetes. The investigators will investigate the vascular function, cardiovascular performance and myocardial fibrosis in different cohorts of subjects to try and prove this hypothesis. There will be 5 groups of subjects, all ≥ 70 years of age, as follows: A) Normal healthy volunteers without major comorbidities including hypertension or diabetes B) Patients with hypertension only (without diabetes mellitus) C) Patients with hypertension AND diabetes mellitus D) Patients with HFpEF. E) A parallel group of patients with Heart Failure with reduced Ejection Fraction (HFrEF) group. Arterial resistance measured by pulse wave velocity will be the primary measure and will be compared between groups A to D. A separate comparison will be made between groups D and E. Other secondary measures will focus on endothelial function (Laser Doppler measurements) and other cardiovascular performance measures (peak VO2 by CPEX, 6-minute walk distance). Bloods samples will be taken for NT-proBNP, high sensitivity Troponin T, Galectin 3 and also stored for testing later for vascular biomarkers.

NCT ID: NCT03184311 Not yet recruiting - Clinical trials for Heart Failure With Normal Ejection Fraction

High-intensity Interval Training in Heart Failure Patients With Preserved Ejection Fraction

Start date: October 1, 2017
Phase: N/A
Study type: Interventional

This study investigates the effects of a 12-week high-intensity interval training (HIT) on exercise tolerance, functional status and quality of life in patients with chronic heart failure with preserved ejection fraction (HFpEF), in comparison to a control group continuing to undergo usual care.

NCT ID: NCT03141567 Recruiting - Heart Failure Clinical Trials

LYmphangiogenesis FacTors in Heart Failure States

Start date: May 18, 2017
Phase: N/A
Study type: Observational

Heart failure often causes fluid to accumulate in the body, leading to congestion and swelling. However, some people who have had heart failure for a long time seem to have very little congestion or swelling, even when the heart failure is poorly treated. The investigators think that this is because lymphatic vessels are able to grow and remove fluid to prevent congestion. The investigators do not know how lymphatic vessels grow. This study will investigate the blood levels of various proteins to try to figure out how the lymph vessels of people with long-standing heart failure might grow.

NCT ID: NCT03099889 Active, not recruiting - Heart Failure Clinical Trials

WHISH-2-Prevent Heart Failure

Start date: April 15, 2015
Phase: N/A
Study type: Interventional

The WHISH-2-Prevent Heart Failure (HF) study is an ancillary study to the Women's Health Initiative Strong and Healthy (WHISH) exercise pragmatic trial. The WHISH-2-Prevent HF trial examines the intervention effect of physical activity (PA) on both incident HF and HF burden (recurrent HF and CVD death in those with HF) in a cost effective manner in elderly women. In addition, it will allow a dose-finding analysis to better understand the type, intensity and frequency of PA that leads to a reduced risk and burden of HF. The focus of the parent WHISH trial is on atherosclerotic cardiovascular disease and not heart failure.